Epo delivery by genetically engineered C2C12 myoblasts immobilized in microcapsules.
ver the last half century, the use of erythropoietin (Epo) in the management of malignancies has been extensively studied. Originally viewed as the renal hormone responsible for red blood cell production, many recent in vivo and clinical approaches demonstrate that various tissues locally produce Epo in response to physical or metabolic stress. Thus, not only its circulating erythrocyte mass regulator activity but also the recently discovered nonhematological actions are being thoroughly investigated in order to fulfill the specific Epo delivery requirements for each therapeutic approach.
Murua
Ainhoa
A
Faculty of Pharmacy, Laboratory of Pharmacy and Pharmaceutical Technology, University of the Basque Country, Vitoria-Gasteiz, Spain.
Orive
Gorka
G
Hernandez
Rosa M
RM
Pedraz
José Luis
JL
D000740:Anemia / Q000188:drug therapy; D000818:Animals; D002460:Cell Line; D018914:Cells, Immobilized; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D005818:Genetic Engineering; D006801:Humans; D020007:Implants, Experimental; D032446:Myoblasts / Q000166:cytology / Q000502:physiology* / Q000637:transplantation*; D011108:Polymers / Q000737:chemistry / Q000378:metabolism; D011994:Recombinant Proteins
D011108:Polymers; D011994:Recombinant Proteins; D004921:Erythropoietin